Why the study?
NOACs are recommended first-line for VTE, but morbidly obese patients were under-represented in landmark trials.
Population
30,895 morbidly obese patients with VTE across eight studies
Comparison
Factor Xa inhibitors (xabans) vs vitamin K antagonists (VKAs)
Design
Systematic review and meta-analysis
Authors
Loading...
No significant recurrent VTE difference; extends evidence of major bleeding reduction with factor Xa inhibitors versus vitamin K antagonists.
Key points are not available for this paper at this time.
Park et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: